About MOLECULIN BIOTECH INC
Moleculin is a biotechnology company advancing a late-stage pipeline of product candidates for the treatment of hard-to-treat tumors and viruses, with a lead program, Annamycin, planning to commence a pivotal Phase 3 clinical trial for 2nd line acute myeloid leukemia (AML).
Development of innovative therapies for hard-to-treat tumors and virusesConducting clinical trials including Phase 3 studies for AML and Phase 1B/2 studies for STS and AML
Is this your company?
Claim MOLECULIN BIOTECH INC to unlock the federal & state contracts GovIntel's AI has matched to you right now — plus your own scored past-performance, who you're up against, and who's risky to team with.
Claim MOLECULIN BIOTECH INC & see your matchesFree to claim. Takes about a minute.
Data compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.